Sarepta Therapeutics Cash Flow - Annual (NASDAQ:SRPT)

Add to My Stocks
$42.54 $1.41 (3.21%) SRPT stock closing price Jul 25, 2017 (Closing)

The financial analysis of SRPT requires an investor to check the cash flows for Sarepta Therapeutics. While its important to look at the Sarepta Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Sarepta Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. The cash flow statement is essetial while conducting the Sarepta Therapeutics cash flow analysis and can be used to measure the operating performance of Sarepta Therapeutics compared to various industry peers like KYTH stock and DBVT stock. Sarepta Therapeutics had an outflow of $96.36M from operating activities, $230.32M inflow due to financing activities, and $98.6M spend due to investing activities for 2016. View details of Sarepta Therapeutics cash flows for latest & last ten financial years.

show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Sarepta Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow5.69M5.89M6.12M1.27M1.52M1.3M1.46M1.37M1.46M2.01M
Net Increase (Decrease) in Assets Liabilities-15.76M31.98M-22.13M12.26M-5.3M6.93M-0.35M2.93M-2.82M-0.35M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net31.52M32.68M23.26M33.74M95.37M-29.59M15.85M12.04M12.96M0.83M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-5.34M-3.4M-25.44M-2.37M-0.1M-1.17M-0.83M-0.93M-0.36M-1.27M
Acquisition Disposition of Subsidiaires---------0.01M-
Increase (Decrease) in Investments-83.32M13.24M-132.2M-7.89M---0.01M0.11M-0.01M12.7M
Other Cash Inflow (Outflow) from Investment Activities-1.52M-1.43M-1.38M-1.4M-1.03M-1.12M-1.12M-1.06M-0.84M-0.85M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares385.73M130.8M104.24M145.98M178.68M32.38M2.56M47.84M0.08M18.74M
Issuance (Repayment) of Debt Securities-7.6M17M-0.09M-0.08M-0.08M-0.08M-0.07M-0.07M-0.11M-
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities
Sarepta Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year80.3M73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M20.15M
Cash & Equivalents at Year End122.42M80.3M73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Sarepta Therapeutics stock price history and Sarepta Therapeutics stock comparison chart inevitably reflect its cash flow situation.
  • Sarepta Therapeutics has cash of $122.42M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Sarepta Therapeutics stock price.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-245.82M for SRPT.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc. , and was $-245.82M for SRPT in last year report.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Sarepta Therapeutics earned $230.32M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Sarepta Therapeutics Cash Flow

FCF margin